Method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug

• US 5,003,098 A
• Filed: 07/01/1988
• Issued: 03/26/1991
• Est. Priority Date: 10/23/1984
• Status: Expired due to Fees

• Current Assignee: Perstorp AB
• Original Assignee: Perstorp AB
• Inventors: Blake, David, Siren, Matti
• Primary Examiner(s): Lone, Werren B.
• Assistant Examiner(s): PAGE, MARGARET
• Application Number:
  US07/214,500
• Time in Patent Office: 998 Days
• Field of Search: 514/103, 514/970, 558/155
• US Class Current: 558/155
• CPC Class Codes: A21D 2/30 Organic phosphorus compounds
• CPC Class Codes: A23B 7/154 Organic compounds; Microorganisms; Enzymes
• CPC Class Codes: A23L 29/05 containing phosphorus as heteroatom
• CPC Class Codes: A23L 3/3553 Organic compounds containing phosphorus
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 39/02 Antidotes
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07F 9/117 with cycloaliphatic alcohols
• CPC Class Codes: C12P 9/00 Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen phosphoglycerides, C12P7/6481

Abstract

A method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug is disclosed. The method comprises administering to an animal or a human an amount of at least one specific isomer of inositol triphosphate sufficient to reduce or eliminate said adverse effects.

Claims

1. A method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug comprising administering to an animal or a human who has suffered adverse effects of a pharmaceutical composition or a drug, an amount of at least one specific isomer selected from the group consisting of D-myo-inositol-1,2,6-triphosphate, myo-inositol-1,2,3-triphosphate and L-myo-inositol-1,3,4-triphosphate sufficient to reduce or eliminate said adverse effects.

2. A method according to claim 1, wherein the adverse effects depend on a disturbed metal balance in the body.

3. A method according to claim 1, wherein the adverse effects depend on free radical formation in the body.

4. A method according to claim 1, wherein the pharmaceutical composition or drug and the isomer of inositol triphosphate are administered separately.

5. A method according to claim 1, wherein the pharmaceutical composition or drug is used against iron overload.

6. A method according to claim 1, wherein the adverse effect caused by the pharmaceutical composition or drug is damage to the eye.

7. A method according to claim 1, wherein the adverse effect caused by the pharmaceutical composition or drug is damage to the cell membrane.